Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice

Blood

Volumn 90, Issue 11, 1997, Pages 4651-4660

  Yang, Yong Guang ^a   Sergio, Justin J ^a   Pearson, Denise A ^a   Szot, Gregory L ^a   Shimizu, Akira ^a   Sykes, Megan ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; INTERLEUKIN 12;

ACCESSORY CELL; ADOPTIVE TRANSFER; ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; LEUKEMIA; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TISSUE CULTURE;

EID: 0030709464     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.11.4651     Document Type: Article

References (67)

1. Gale RP: Graft-versus-host disease. Immunologic Rev 88:193, 1985
2. Ringden O, Nilsson B: Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy. Transplantation 40:39, 1985
3. Martin PJ, Hansen JA, Torok-Storb B, Durnam D, Przepiorka D, O'Quigley J, Sanders J, Sullivan KM, Witherspoon RP, Deeg HJ, Appelbaum FR, Stewart P, Weiden P, Doney K, Buckner CD, Clift R, Storb R, Thomas ED: Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant 3:445, 1988
4. Poynton CH: T cell depletion in bone marrow transplantation. Bone Marrow Transplant 3:265, 1988
5. Butturini A, Gale RP: T cell depletion in bone marrow transplantation for leukemia: Current results and future directions. Bone Marrow Transplant 3:265, 1988
6. Gajewski JL, Ho WG, Feig SA, Hunt L, Kaufman N, Champlin RE: Bone marrow transplantation using unrelated donors for patients with advanced leukemia or bone marrow failure. Transplantation 50:244, 1990
7. Beatty PG, Clift RA, Mickelson FM, Nisperos BB, Flournoy N, Martin PJ, Sanders JE, Stewart P, Buckner CD, Storb R, Thomas ED, Hansen JA: Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 313:765, 1985
8. Bortin MM: Bone marrow transplantation for leukemia using family donors other than HLA-identical siblings: A preliminary report from the International Bone Marrow Transplant Registry. Transplant Proc 19:2629, 1987
9. Beatty PG, Anasetti C, Hansen JA, Longton GM, Sanders JE, Martin PJ, Mickelson EM, Choo SY, Petersdorf EW, Pepe MS, Appelbaum FR, Bearman SI, Buckner CD, Clift RA, Petersen FB, Singer J, Stewart PS, Storb RF, Sullivan KM, Tesler MC, Witherspoon RP, Thomas ED: Marrow transplantation from unrelated donors for treatment of hematologic malignancies: Effect of mismatching for one HLA locus. Blood 81:249, 1993
10. Sykes M, Romick ML, Hoyles KA, Sachs DH: In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloen-graftment. J Exp Med 171:645, 1990
11. Sykes M, Romick ML, Sachs DH: Interleukin 2 prevents graft-vs-host disease while preserving the graft-vs-leukemia effect of allogeneic T cells. Proc Natl Acad Sci USA 87:5633, 1990
12. Sykes M, Abraham VS, Harty MW, Pearson DA: IL-2 reduces graft-vs-host disease and preserves a graft-vs-leukemia effect by selectively inhibiting CD4+ T cell activity. J Immunol 150:197, 1993
13. Sykes M, Harty MW, Szot GL, Pearson DA: Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CDS-mediated graft-versus-leukemia effects. Blood 83:2560, 1994
14. D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Aste-Amezaga M, Chen SH, Kobayashi M, Young D, Nickbarg E, Chizzonite R, Wolf SF, Trinchieri G: Production of natural killer cell stimulatory factor interleukin 12 by peripheral blood mononuclear cells. J Exp Med 176:1387, 1992
15. Manetti R, Parronchi P, Giudizi MG, Piccini M-P, Maggi E, Trinchieri G, Romagnani S: Natural killer cell stimulatory factor (Interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 177:1199, 1993
16. Seder RA, Gazzinelli R, Sher A, Paul WE: Interleukin-12 acts directly on CD4+ T cells to enhance priming for interferon-gamma production and diminishes interleukin-4 inhibition of such priming. Proc Natl Acad Sci USA 90:10188, 1993
17. Trinchieri G: Interleukin-12 and its role in the generation of Th1 cells. Immunol Today 14:335, 1993
18. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Ludon R, Sherman F, Perussia B, Trinchieri G: Identification and purification of natural killer stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170:827, 1989
19. Brunda MJ, Luistro L, Warner RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178:1223, 1993
20. Hashimoto W, Takeda K, Anzai R, Ogasawara K, Sakihara H, Sugiura K, Seki S, Kumagai K: Cytotoxic NK1.1 Ag+ ab T cells with intermediate TCR induced in the liver of mice by IL-12. J Immunol 154:4333, 1995
21. Sykes M, Szot GL, Nguyen PL, Pearson DA: Interleukin-12 inhibits murine graft-vs-host disease. Blood 86:2429, 1995
22. Dialynas DP, Quan ZS, Wall KA, Pierres A, Quintans J, Loken MR, Pierres M, Fitch FW: Characterization of murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: Similarity of L3T4 to human Leu3/T4 molecule. J Immunol 131:2445, 1983
23. Sarmiento M, Glasebrook AL, Fitch FW: IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt2 antigen block T cell-mediated cytolysis in the absence of complement. J Immunol 125:2665, 1980
24. Sykes M, Sharabi Y, Sachs DH: Natural suppressor cells in spleens of irradiated, bone marrow reconstituted mice and normal bone marrow: Lack of Sca-1 expression and enrichment by depletion of Mac1-positive cells. Cell Immunol 127:260, 1990
25. Sykes M, Bukhari Z, Sachs DH: Graft-versus-leukemia effect using mixed allogeneic bone marrow transplantation. Bone Marrow Transplant 4:465, 1989
26. Tomita Y, Sachs DH, Sykes M: Myelosuppressive conditioning is required to achieve engraftment of pluripotent stem cells contained in moderate doses of syngeneic bone marrow. Blood 83:939, 1994
27. Ozato K, Mayer NM, Sachs DH: Monoclonal antibodies to mouse major histocompatibility complex antigens IV. A series of hybridoma clones producing anti-H-2d antibodies and an examination of expression of H-2d antigens on the surface of these cells. Transplantation 34:113, 1982
28. Unkeless JC: Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J Exp Med 150:580, 1979
29. Spitalny GL, Havell EA: Monoclonal antibody to murine gamma interferon inhibits lymphokine-induced antiviral and macrophage tumoricidal activity. J Exp Med 159:1560, 1984
30. Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Stephany D, Sachs DH: Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host desease in mixed allogeneic chimeras (B10 + B10.D2 → B10). J Immunol 136:28, 1896
31. Sykes M, Sheard M, Sachs DH: Effects of T cell depletion in radiation bone marrow chimeras. Evidence for a donor cell population which increases allogeneic chimerism but which lacks the potential to produce GVHD. J Immunol 141:2282, 1988
32. Singer A, Hathcock KS, Modes RJ: Self recognition in allogeneic radiation chimeras. A radiation resistant host element dictates the self specificity and immune response gene phenotype of T-helper cells. J Exp Med 153:1286, 1981
33. Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Sachs DH: Characterization of mixed allogeneic chimeras. Immunocompetence, in vitro reactivity, and genetic specificity of tolerance. J Exp Med 162:231, 1985
34. Ildstad ST, Sachs DH: Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 307:168, 1984
35. Szebeni J, Wang M-G, Pearson DA, Szot GL, Sykes M: IL-2 inhibits early increases in serum gamma interferon levels associated with graft-vs-host disease. Transplantation 58:1385, 1994
36. Butturini A, Bortin MM, Gale RP: Graft-versus-leukemia following bone marrow transplantation. Bone Marrow Transplant 2:233, 1987
37. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb H-J, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555, 1990
38. Butturini A, Gale RP: The role of T-cells in preventing relapse in chronic myelogenous leukemia. Bone Marrow Transplant 2:351, 1987
39. Westcott O, Dorsch S, Roser B: Adoptive immunotherapy of leukemia in the rat, without grart-vs-host complications. J Immunol 123:1478, 1979
40. Bortin MM, Truitt RL, Rimm AA, Bach FH: Graft-versus-leukaemia reactivity induced by alloimmunisation without augmentation of graft-versus-host reactivity. Nature 281:490, 1979
41. LeFever AV, Truitt RL, Shih CC-Y: Reactivity of in vitro-expanded alloimmune cytotoxic T lymphocytes and Qa1-specific cytotoxic T lymphocytes against AKR leukemia in vivo. Transplantation 40:531, 1985
42. Slavin S, Weiss L, Morecki S, Weigensberg M: Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother 11:155, 1981
43. Cheever MA, Greenberg PD, Fefer A: Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and non-specifically expanded by culture with interleukin 2. J Immunol 126:1318, 1981
44. Dailey MO, Pillemer E, Weissman IL: Protection against syngeneic lymphoma by a long-lived cytotoxic T cell clone. Proc Natl Acad Sci USA 79:5384, 1982
45. Donohue JH, Rosenstein M, Chang AE, Lotze MT, Robb RJ, Rosenberg SA: The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma. J Immunol 132:2123, 1984
46. Sykes M, Sachs DH: Genetic analysis of the anti-leukemic effect of mixed allogeneic bone marrow transplantation. Transplant Proc 21:3022, 1989
47. Mehrotra PT, Wu D, Crim JA, Mostowki HS, Siegel JP: Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. J Immunol 151:2444, 1993
48. Gately MK, Desai BB, Wolitzky AG, Quinn PM, Dwyer CM, Podlaski FJ, Familletti PC, Sinigaglia F, Chizonnite R, Gubler U, Stern AS: Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 147:874, 1991
49. Orange JS, Wolf SF, Biron CA: Effects of IL-12 on the response and susceptibility to experimental viral infections. J Immunol 152:1253, 1994
50. Chouaib S, Chehimi J, Bani L, Genetet N, Tursz T, Gay F, Trinchieri G, Mami-Chouaib F: Ineterleukin-12 induces the differentiation of major histocompatibility complex class I-primed cytotoxic T-lymphocyte precursors into allospecific cytotoxic effectors. Proc Natl Acad Sci USA 91:12659, 1994
51. Pietryga D, Blazar BR, Soderling CB, Vallera DA: The effect of T subset depletion on the incidence of lethal graft-versus-host disease in a murine major-histocompatibility-complex-mismatched transplantation system. Transplantation 43:442, 1987
52. Korngold R, Sprent J: Surface markers of T cells causing lethal graft-vs-host disease to class I vs class II H-2 differences. J Immunol 135:3004, 1985
53. Vallera DA, Soderling CCB, Kersey JH: Bone marrow transplantation across major histocompatibility barriers in mice. III. Treatment of donor grafts with monoclonal antibodies directed against Lyt determinants. J Immunol 128:871, 1982
54. Uenaka A, Mieno M, Kuribayashi K, Shiku H, Nakayama E: Effector cells of lethal graft-versus-host disease (GVHD) in nude mice. Transplant Proc 21:3031, 1989
55. Thiele DL, Charley MR, Calomeni JA, Lipsky PE: Lethal graft-vs-host disease across major histocompatibility barriers: Requirement for leucyl-leucine methyl ester sensitive cytotoxic T cells. J Immunol 138:51, 1987
56. Wang M-G, Szebeni J, Pearson DA, Szot GL, Sykes M: Inhibition of graft-vs-host disease (GVHD) by IL-2 treatment is associated with altered cytokine production by expanded GVH-reactive CD4+ helper cells. Transplantation 60:481, 1995
57. Niederwieser D, Herold M, Woloszczuk W, Aulitzky W, Meister B, Tilg H, Gastl G, Bowden R, Huber C: Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of Interferon and interferon-dependent secondary messages. Transplantation 50:620, 1990
58. Alien RD, Staley TA, Sidman CL: Differential cytokine expression in acute and chronic murine graft-versus-host disease. Eur J Immunol 23:333, 1993
59. Guy-Grand D, Vassalli P: Gut injury in mouse graft-vs-host reaction: Study of its occurrence and mechanism. J Clin Invest 77:1584, 1986
60. Mowat AM: Antibodies to IFN-gamma prevent immunologiCally mediated intestinal damage in murine graft-versus-host reaction. Immunology 68:18, 1989
61. Kumpel GR, Annable GR, Cleveland MG, Jerrells TR, Patterson JC: Immunosuppression and lymphoid hypoplasia associated with chronic graft versus host disease is dependent upon IFN-gamma production. J Immunol 144:84, 1990
62. Brok HPM, Heidt PJ, Van der Meide PH, Zurcher C, Vossen JM: Interferon-gamma prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Immunol 151:6451, 1993
63. Tannenbaum CS, Wicker N, Armstrong D, Tubbs R, Finke J, Bukowski RM, Hamilton TA: Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol 156:693, 1996
64. Brunda MJ, Sulich V, Bellantoni D: The anti-tumor effect of recombinant interferon alpha and gamma is influenced by tumor location. Int J Cancer 40:807, 1987
65. Truitt RL, Atasoylu AA: Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant 8:51, 1991
66. Korngold R, Leighton C, Manser T: Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation. Transplantation 58:278, 1994
67. Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beatty P, Bensinger W, Berenson R, Buckner CD, Clift R, Doney K, Longton G, Hansen J, Hill R, Loughran TJ, Martin P, Singer J, Sanders J, Stewart P, Sullivan K, Witherspoon R, Thomas ED: Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 73:1729, 1989